Despite the very positive setup facing Amgen as a result of its ongoing and future investments in developing new cardiometabolic medicines for big-ticket indications like obesity and type 2 diabetes, ...
The recent volatility in key GLP-1 stocks has put the spotlight on the anxiety Wall Street has about the weight loss market. The market is huge — a potential $150 billion a year by the end of the ...